Author

Grigore Gafencu

University of OxfordORCID 0000-0001-6369-3201Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Adrian H. TayloriD· 1 shared Alexander Murison· 1 shared Alicia G. Aguilar-NavarroiD· 1 shared Alison KennedyiD· 1 shared Ancuta Jurj· 1 shared Andrew Jonathan CarriD· 1 shared Andy G. X. ZengiD· 1 shared Batchimeg UsukhbayariD· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrian H. TaylorORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell stem cellPeer-reviewedJun 24, 2024

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Niels Asger Jakobsen, Sven Turkalj, Andy G. X. Zeng…·Paresh Vyas

This study identifies how DNMT3A and TET2 mutations in hematopoietic stem cells confer a selective advantage by reducing inflammation and aging effects.

165 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 5, 2018

DNMT3A-NPM1 mutated acute myeloid leukaemia shows sensitivity to a PARP1 inhibitor combined with daunorubicin in an in vitro model

Grigore Gafencu, Valentina Pileczki, Ancuta Jurj…·Ciprian Tomuleasa

The paper tests if PARP inhibitors combined with anthracyclines are effective against DNMT3A-NPM1 mutated AML in vitro, finding similar sensitivity to MLL-AF9 mutated leukaemias.

DOI 10.1101/362103

humanbulk RNA-seq

𝕏 PostBluesky